We have demonstrated that AZ5576, a selective CDK9-inhibitor, led to rapid downmodulation of MYC and Mcl-1 in diffuse large B-cell lymphoma (DBLCL), accompanied by a shutdown of the MYC transcriptional program and apoptosis [2]. The gene discussed is CDK9; the disease is diffuse large B-cell lymphoma.